Efficacy of Galeo® in Patients With Postprandial Distress Syndrome Subtype in Functional Dyspepsia
Status:
Not yet recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The investigators conduct a randomized, double-blind, placebo-controlled study to investigate
the effects of Galeo® on dyspepsia symptoms in patients with postprandial distress syndrome
subtype in functional dyspepsia for 8 weeks.